Invention Application
![PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS](/docs/US/2017-01-12/US20170008885A1/abs.jpg.600x600.jpg)
- Patent Title: PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS
- Patent Title (中): 吡咯并[3,2-C]吡啶衍生物作为TLR抑制剂
-
Application No.: US15103900Application Date: 2014-12-12
-
Publication No.: US20170008885A1Publication Date: 2017-01-12
- Inventor: Summon KOUL , Suresh KURHADE , Sandeep BHOSALE , Keshav NAIK , Videsh SALUNKHE , Yogesh MUNOT , Debnath BHUNIYA
- Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Applicant Address: JP Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka
- Priority: IN3656/DEL/2013 20131213
- International Application: PCT/JP2014/083630 WO 20141212
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D519/00
![PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS](/abs-image/US/2017/01/12/US20170008885A1/abs.jpg.150x150.jpg)
Abstract:
The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7/8, TLR7/9 or TLR7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
Public/Granted literature
- US09643967B2 Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors Public/Granted day:2017-05-09
Information query
